Upon tagging the LNP with anti-EGFR antibodies, 3-fold higher tumor accumulation compared to isotype controls and selective uptake into disseminated ovarian tumors was detected. RNA release and expression were very rapid, with therapeutic effects observed within 48 hours. PLK1 gene editing achieved an average of 82% efficacy in tumor cells and remained less than 1% in normal ones. Consequently, more efficient tumor growth inhibition and an 80% increase in patients' survival rate were achieved. The gene discussed is PLK1; the disease is neoplasm.